Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05194111
PHASE1/PHASE2

Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan

Sponsor: Virginia Commonwealth University

View on ClinicalTrials.gov

Summary

To determine feasibility of recruitment and tolerability of treatment with sacubitril-valsartan among adult age survivors of cancer diagnosed at or before age 39 who have stage B heart failure.

Official title: Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan (Treat HF)

Key Details

Gender

All

Age Range

18 Years - 120 Years

Study Type

INTERVENTIONAL

Enrollment

53

Start Date

2022-08-11

Completion Date

2028-11-30

Last Updated

2026-03-13

Healthy Volunteers

No

Interventions

DRUG

Sacubitril-valsartan

Administered orally twice daily at a maximally tolerate dose (max dose 97mg/103mg twice daily).

DRUG

Valsartan

Administered orally twice daily at a maximally tolerate dose (max dose 160mg twice daily)

Locations (1)

Virginia Commonwealth University

Richmond, Virginia, United States